Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

Hepatozyten-Wachstumsfaktor-Rezeptor

Das MET-Gen kodiert eine Tyrosinkinaserezeptor, der wenn an an Hepatozytenwachstumsfaktor gebunden eine wichtige Rolle beim Zellüberleben, Embryogenese, Migration und Invassion spielt. Mutationen werden bei verschiedenen Tumoren gesehen: papilläres Nierenzellkarzinom, hepatozelluläres Karzinom und verschiedene weitere Tumoren im Kopf- und Hals-Bereich.

Gentests:

Klinisch Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Forschung Untersuchungsmethoden Multiplex ligationsabhängige Amplifikation
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Erbliche Schwerhörigkeit 97
MET
Hepatozelluläres Karzinom
MET
Hereditäres papilläres Nierenzellkarzinom 1
MET
Osteofibröse dysplasie
MET

Referenzen:

1.

Beals RK et al. (1976) Familial congenital bowing of the tibia with pseudarthrosis and pectus excavatum: report of a kindred.

external link
2.

Finisguerra V et al. (2015) MET is required for the recruitment of anti-tumoural neutrophils.

external link
3.

Rodgers JT et al. (2014) mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert).

external link
4.

Kaushansky A et al. (2011) The crucial role of hepatocyte growth factor receptor during liver-stage infection is not conserved among Plasmodium species.

external link
5.

Zou C et al. (2007) Lack of Fas antagonism by Met in human fatty liver disease.

external link
6.

Engelman JA et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

external link
7.

Campbell DB et al. (2006) A genetic variant that disrupts MET transcription is associated with autism.

external link
8.

Veiga E et al. (2005) Listeria hijacks the clathrin-dependent endocytic machinery to invade mammalian cells.

external link
9.

Carrolo M et al. (2003) Hepatocyte growth factor and its receptor are required for malaria infection.

external link
10.

Giordano S et al. (2002) The semaphorin 4D receptor controls invasive growth by coupling with Met.

external link
11.

Maina F et al. (2001) Coupling Met to specific pathways results in distinct developmental outcomes.

external link
12.

Powell EM et al. (2001) Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon.

external link
13.

Shen Y et al. (2000) InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase.

external link
14.

Park WS et al. (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.

external link
15.

Jeffers M et al. (1998) The mutationally activated Met receptor mediates motility and metastasis.

external link
16.

Schmidt L et al. (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.

external link
17.

Jeffers M et al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer.

external link
18.

Mujtaba G et al. (2015) A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss.

external link
19.

Sunkara UK et al. (1997) Bilateral osteofibrous dysplasia: a report of two cases and review of the literature.

external link
20.

Karol LA et al. (2005) Familial osteofibrous dysplasia. A case series.

external link
21.

Gray MJ et al. (2015) Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

external link
22.

Schmidt L et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

external link
23.

Zhuang Z et al. (1998) Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.

external link
24.

Boccaccio C et al. (2005) The MET oncogene drives a genetic programme linking cancer to haemostasis.

external link
25.

None (1992) The met oncogene: from detection by transfection to transmembrane receptor for hepatocyte growth factor.

external link
26.

Bottaro DP et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

external link
27.

Park M et al. (1987) Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

external link
28.

Dean M et al. (1987) Chromosomal localization of the met proto-oncogene in the mouse and cat genome.

external link
29.

Dean M et al. () The human met oncogene is related to the tyrosine kinase oncogenes.

external link
30.

Cooper CS et al. () Molecular cloning of a new transforming gene from a chemically transformed human cell line.

external link
31.

Maina F et al. (1996) Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development.

external link
32.

Giordano S et al. (1997) A point mutation in the MET oncogene abrogates metastasis without affecting transformation.

external link
33.

NCBI article

NCBI 4233 external link
34.

OMIM.ORG article

Omim 164860 external link
35.

Orphanet article

Orphanet ID 123201 external link
Update: 14. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz